News Releases

TORONTO Dec. 21, 2022 Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its AI.ME next generation robotic technology

TORONTO , Nov. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has completed a non-brokered private placement (the “Private Placement”) of convertible preferred stock (the

TORONTO , Nov. 10, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2022 . Third Quarter 2022 Summary & Operating Highlights:

TORONTO , Oct. 19, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has issued a stock option inducement grant to its President and Chief Business Officer, Hemanth Varghese , upon the

TORONTO , Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022 .

TORONTO , Oct. 06, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has issued a stock option inducement grant to its Chief Executive Officer, Rajiv De Silva , upon the execution of

TORONTO , Oct. 05, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it is updating the release date for its third quarter of fiscal year 2022 financial results.

TORONTO , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that Rajiv De Silva has been appointed as the Company’s Chief Executive Officer and a member of the Board of Directors (the

TORONTO , Aug. 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2022 . Second Quarter 2022 Summary & Operating Highlights: Total

TORONTO , June 30, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2022 financial results will be released before the market opens on Friday, August 12,

TORONTO , May 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2022 . First Quarter 2022 Summary & Recent Highlights: Total revenue of

Clearance Expands Indications for Use to Include Non-Invasive Lipolysis of the Back and Thighs and Increases Maximum Energy Output to 150 Watts TORONTO , April 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology

TORONTO , April 25, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that the first patient has been treated in a U.S. Investigational Device Exemption (IDE) clinical study evaluating the

TORONTO , April 04, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2022 financial results will be released after the market closes on Thursday, May 12,

TORONTO , March 31, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced it has submitted a 510(k) premarket notification (“510(k)”) to the U.S. Food and Drug Administration ("FDA"), which is

TORONTO , March 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2021 . Fourth Quarter 2021 Summary & Recent Highlights:

TORONTO , March 21, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”)  (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will present at the Maxim Virtual Growth Conference , which is being held virtually from March 28th-30th

TORONTO , Feb. 08, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”)  (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the BTIG Virtual MedTech, Digital Health , Life Science & Diagnostic Tools Conference

TORONTO , Feb. 02, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Monday, March 28,

TORONTO , Jan. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus BlissMAX

TORONTO , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“ Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited revenue results for the three months ended December 31, 2021 .